Transcatheter Mitral Valve Replacement With the Medtronic Intrepid™ TMVR System in Patients With Severe Symptomatic Mitral Regurgitation (APOLLO)
Diseases of the Cardiovascular System
What is the purpose of this trial?
Multi-center, global, prospective, randomized, interventional, pre-market trial with two subject groups: the randomized group will be randomized on 1:1 basis to either the study device or to conventional mitral valve surgery. Subjects in the single-arm group will receive the study device.
Subjects will be seen at pre- and post-procedure, discharge, 30 days, 6 months, and annually through 5 years.
- Ages18 years and older
- Trial withMedtronic, Inc
- Start Date03/04/2018
- End Date10/30/2021
- Last Updated01/17/2019
- Study HIC#2000021883